Figure 1. Optimisation of bortezomib concentration by comparison with 10 µM MG132. (A) Schematic of the experimental workflow. HFFF-TERT cells were infected with Merlin strain HCMV (MOI 5) or mock infected and simultaneously treated with 10 µM MG132, 500 nM, 1 µM or 2 µM bortezomib. Samples were harvested at 12 hpi to maximise the ability to study very early infection as we previously described (Nightingale et al., 2018). Whole cell lysates were digested into peptides, which were labelled with TMT reagents followed by MS3 mass spectrometry. (B) Comparison of 10µM MG132 with 500 nM, 1 µM or 2 µM bortezomib (bort).